Atara Biotherapeutics, Inc. Q1 FY2022 earnings call

• ATA188: Progress with 2 landmark publications, EBV and MS Day, updated Phase I data; on track for Phase II EMBOLD interim analysis in June, plan to communicate IA decisions and rationale in July, discuss with FDA and partnering.
• tab-cel: On track for EU EC approval in Q4 2022, EMA requested additional time but still expect Q4 approval, pre-approval inspections confirmed, comparability data submitted to EMA.
• CAR T programs: ATA2271 had a fatal adverse event but Atara believes not caused by the product, ATA3271 IND filing in Q4, ATA3219 on track to submit IND in Q4 with unique features.
• Operational updates: Hired Chief Technical Officer, sold manufacturing facility to FUJIFILM Diosynth Biotechnologies, cash position $302M as of Q1 2022.

ATA188: Made progress with 2 landmark publications in Nature and Science, conducted EBV and MS Day with updated Phase I data showing majority of patients had EDSS improvement/stability; on track for Phase II EMBOLD interim analysis in June. tab-cel: On track for EU EC approval in Q4 2022, EMA requested additional time but still expect Q4 approval, pre-approval inspections confirmed, comparability data submitted to EMA. CAR T programs: ATA2271 had a fatal adverse event but Atara believes not caused by the product, ATA3271 IND filing in Q4, ATA3219 on track to submit IND in Q4 with unique features. Operational updates: Hired Chief Technical Officer, sold manufacturing facility to FUJIFILM Diosynth Biotechnologies, cash position $302M as of Q1 2022.

• ATA188: On track for Phase II EMBOLD interim analysis in June, plan to communicate IA decisions and rationale in July, discuss with FDA and partnering.
• tab-cel: Expect EC approval in Q4 2022, ongoing dialogue with FDA for BLA filing without new Phase III study.
• CAR T programs: ATA3271 IND filing in Q4, ATA3219 IND submission in Q4.

• ATA188: Uncertainty around IA results and sample size adjustments.
• tab-cel: Uncertainty in FDA BLA review process, potential need for additional studies.
• ATA2271: Pause in enrollment due to fatal adverse event, pending final assessment.

Q: Salim Syed asked about ATA188 IA interpretation and if it would be an interpretable readout, A: Pascal Touchon Q: Tessa Romero asked about tab-cel EU approval and ATA188 activities, A: Jakob Dupont and AJ Joshi Q: John Newman asked if clear separation between ATA188 and placebo at interim could be disclosed in Q3 and about 12-month data, A: Pascal Touchon Q: Marc Frahm asked about EMA comparability and tab-cel commercial lots, A: Pascal Touchon Q: Neil Carnahan asked about ATA2271 patient death cause, A: Jakob Dupont Q: Jonathan Miller asked about ATA188 IA stats and tab-cel FDA dialogue, A: AJ Joshi and Jakob Dupont Q: Matt Sykes asked about tab-cel multi-cohort data and ATA2271 Phase I update, A: Jakob Dupont Q: Yigal Nochomovitz asked about ATA188 IA scenarios, A: Pascal Touchon and AJ Joshi Q: Tony Butler asked about communication to clinical sites for ATA188, A: AJ Joshi